Identification of a novel combination treatment strategy in clear cell renal cell carcinoma stem cells with shikonin and ipilimumab

BACKGROUND: Management of clear cell renal cell carcinoma (ccRCC) has changed rapidly in recent years with the advent of immune checkpoint inhibitors (ICIs). However, only a limited number of patients can sustainably respond to immune checkpoint inhibitors and many patients develop resistance to the...

Descripción completa

Detalles Bibliográficos
Autores principales: Lyu, Chen, Stadlbauer, Birgit, Wang, Lili, Buchner, Alexander, Pohla, Heike
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Immunology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10445237/
https://www.ncbi.nlm.nih.gov/pubmed/37622107
http://dx.doi.org/10.3389/fimmu.2023.1186388

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10445237/
https://www.ncbi.nlm.nih.gov/pubmed/37622107
http://dx.doi.org/10.3389/fimmu.2023.1186388

Ejemplares similares